ANI Pharmaceuticals, Inc. (ANIP)
USD 68.72
(0.88%)
USD 68.72
(0.88%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 305.3 Million USD | 38.24% |
| 2022 | 177.6 Million USD | 53.73% |
| 2021 | 115.52 Million USD | -4.77% |
| 2020 | 121.31 Million USD | -15.39% |
| 2019 | 143.39 Million USD | 11.54% |
| 2018 | 128.55 Million USD | 31.43% |
| 2017 | 97.81 Million USD | 22.5% |
| 2016 | 79.84 Million USD | 25.48% |
| 2015 | 63.63 Million USD | 43.0% |
| 2014 | 44.49 Million USD | 121.29% |
| 2013 | 20.1 Million USD | 392.85% |
| 2012 | -6.86 Million USD | -1882.7% |
| 2011 | 385.16 Thousand USD | -82.54% |
| 2010 | 2.2 Million USD | 75.31% |
| 2009 | 1.25 Million USD | -66.73% |
| 2008 | 3.78 Million USD | 666.82% |
| 2007 | 493.05 Thousand USD | -96.59% |
| 2006 | 14.43 Million USD | 5488.76% |
| 2005 | 258.35 Thousand USD | 231.7% |
| 2004 | 77.88 Thousand USD | 18.92% |
| 2003 | 65.49 Thousand USD | -97.69% |
| 2002 | 2.83 Million USD | 62.18% |
| 2001 | 1.74 Million USD | 7093.26% |
| 2000 | 24.29 Thousand USD | 2429100.0% |
| 1999 | 1.00 USD | -100.0% |
| 1998 | 123.06 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 73.58 Million USD | 16.73% |
| 2024 Q2 | 65.64 Million USD | -10.79% |
| 2023 FY | 245.51 Million USD | 38.24% |
| 2023 Q1 | 69.07 Million USD | 19.29% |
| 2023 Q2 | 74.26 Million USD | 7.51% |
| 2023 Q3 | 83.72 Million USD | 12.75% |
| 2023 Q4 | 63.04 Million USD | -24.71% |
| 2022 Q4 | 57.9 Million USD | 13.7% |
| 2022 FY | 177.6 Million USD | 53.73% |
| 2022 Q3 | 50.92 Million USD | 32.07% |
| 2022 Q1 | 30.2 Million USD | 11.75% |
| 2022 Q2 | 38.56 Million USD | 27.66% |
| 2021 Q1 | 34.53 Million USD | 5.58% |
| 2021 Q2 | 26.31 Million USD | -23.82% |
| 2021 FY | 115.52 Million USD | -4.77% |
| 2021 Q3 | 27.64 Million USD | 5.08% |
| 2021 Q4 | 27.03 Million USD | -2.23% |
| 2020 Q2 | 27.77 Million USD | -0.7% |
| 2020 Q1 | 27.97 Million USD | -7.3% |
| 2020 Q3 | 32.86 Million USD | 18.31% |
| 2020 FY | 121.31 Million USD | -15.39% |
| 2020 Q4 | 32.71 Million USD | -0.45% |
| 2019 FY | 143.39 Million USD | 11.54% |
| 2019 Q4 | 30.17 Million USD | -16.96% |
| 2019 Q2 | 38.72 Million USD | 1.48% |
| 2019 Q3 | 36.33 Million USD | -6.17% |
| 2019 Q1 | 38.16 Million USD | 3.17% |
| 2018 Q1 | 25.79 Million USD | -3.91% |
| 2018 Q3 | 35.09 Million USD | 14.42% |
| 2018 Q2 | 30.67 Million USD | 18.94% |
| 2018 FY | 128.55 Million USD | 31.43% |
| 2018 Q4 | 36.98 Million USD | 5.39% |
| 2017 Q4 | 26.84 Million USD | -0.91% |
| 2017 FY | 97.81 Million USD | 22.5% |
| 2017 Q3 | 27.08 Million USD | 14.57% |
| 2017 Q2 | 23.64 Million USD | 16.8% |
| 2017 Q1 | 20.24 Million USD | -4.96% |
| 2016 Q2 | 19.54 Million USD | 13.98% |
| 2016 Q1 | 17.14 Million USD | 18.28% |
| 2016 FY | 79.84 Million USD | 25.48% |
| 2016 Q4 | 21.29 Million USD | -2.55% |
| 2016 Q3 | 21.85 Million USD | 11.84% |
| 2015 Q1 | 16.04 Million USD | -7.58% |
| 2015 Q2 | 16.37 Million USD | 2.04% |
| 2015 FY | 63.63 Million USD | 43.0% |
| 2015 Q3 | 16.71 Million USD | 2.06% |
| 2015 Q4 | 14.49 Million USD | -13.27% |
| 2014 Q3 | 14.32 Million USD | 216.25% |
| 2014 Q2 | 4.53 Million USD | -45.27% |
| 2014 Q4 | 17.36 Million USD | 21.21% |
| 2014 Q1 | 8.27 Million USD | 5.47% |
| 2014 FY | 44.49 Million USD | 121.29% |
| 2013 Q1 | -2.26 Million USD | -149.49% |
| 2013 FY | 20.1 Million USD | 392.85% |
| 2013 Q4 | 7.84 Million USD | 50.72% |
| 2013 Q3 | 5.2 Million USD | 28.48% |
| 2013 Q2 | 4.05 Million USD | 279.1% |
| 2012 Q4 | -907.05 Thousand USD | 58.98% |
| 2012 Q2 | 108.78 Thousand USD | -4.58% |
| 2012 Q1 | 114 Thousand USD | 77.09% |
| 2012 FY | -6.86 Million USD | -1882.7% |
| 2012 Q3 | -2.21 Million USD | -2132.9% |
| 2011 Q3 | 182.78 Thousand USD | 125.65% |
| 2011 Q1 | 57 Thousand USD | -60.15% |
| 2011 FY | 385.16 Thousand USD | -82.54% |
| 2011 Q4 | 64.37 Thousand USD | -64.78% |
| 2011 Q2 | 81 Thousand USD | 42.11% |
| 2010 Q2 | - USD | -100.0% |
| 2010 FY | 2.2 Million USD | 75.31% |
| 2010 Q1 | 2.27 Million USD | 114.28% |
| 2010 Q4 | 143.03 Thousand USD | 178.65% |
| 2010 Q3 | 51.33 Thousand USD | 0.0% |
| 2009 Q1 | 68.42 Thousand USD | -98.1% |
| 2009 FY | 1.25 Million USD | -66.73% |
| 2009 Q3 | 10.49 Thousand USD | -90.89% |
| 2009 Q2 | 115.16 Thousand USD | 68.3% |
| 2009 Q4 | 1.06 Million USD | 10040.78% |
| 2008 Q3 | 82.21 Thousand USD | 217.8% |
| 2008 Q2 | 25.86 Thousand USD | -43.27% |
| 2008 Q1 | 45.59 Thousand USD | -86.15% |
| 2008 FY | 3.78 Million USD | 666.82% |
| 2008 Q4 | 3.6 Million USD | 4290.78% |
| 2007 Q2 | 69.44 Thousand USD | 37.22% |
| 2007 Q3 | 43.79 Thousand USD | -36.94% |
| 2007 Q1 | 50.6 Thousand USD | -99.64% |
| 2007 Q4 | 329.2 Thousand USD | 651.73% |
| 2007 FY | 493.05 Thousand USD | -96.59% |
| 2006 Q1 | 84.67 Thousand USD | -12.68% |
| 2006 FY | 14.43 Million USD | 5488.76% |
| 2006 Q3 | 140.32 Thousand USD | -19.93% |
| 2006 Q4 | 14.03 Million USD | 9904.25% |
| 2006 Q2 | 175.25 Thousand USD | 106.96% |
| 2005 Q2 | 45.59 Thousand USD | 59.0% |
| 2005 Q4 | 96.97 Thousand USD | 11.33% |
| 2005 Q1 | 28.67 Thousand USD | -47.7% |
| 2005 Q3 | 87.1 Thousand USD | 91.04% |
| 2005 FY | 258.35 Thousand USD | 231.7% |
| 2004 Q2 | 4976.00 USD | -31.98% |
| 2004 Q3 | 10.76 Thousand USD | 116.28% |
| 2004 Q4 | 54.83 Thousand USD | 409.5% |
| 2004 FY | 77.88 Thousand USD | 18.92% |
| 2004 Q1 | 7316.00 USD | 113.13% |
| 2003 Q1 | 84.31 Thousand USD | -95.42% |
| 2003 FY | 65.49 Thousand USD | -97.69% |
| 2003 Q4 | -55.7 Thousand USD | -319.33% |
| 2003 Q3 | 25.39 Thousand USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2002 FY | 2.83 Million USD | 62.18% |
| 2002 Q4 | 1.84 Million USD | 91.3% |
| 2002 Q3 | 962.55 Thousand USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 100.0% |
| 2001 Q1 | 1.00 USD | 0.0% |
| 2001 Q4 | -1.79 Million USD | -202.91% |
| 2001 FY | 1.74 Million USD | 7093.26% |
| 2001 Q3 | 1.74 Million USD | 3336.83% |
| 2001 Q2 | 50.84 Thousand USD | 5084200.0% |
| 2000 Q4 | 1.00 USD | 0.0% |
| 2000 Q1 | 1.00 USD | 0.0% |
| 2000 FY | 24.29 Thousand USD | 2429100.0% |
| 2000 Q3 | 1.00 USD | 0.0% |
| 2000 Q2 | 1.00 USD | 0.0% |
| 1999 FY | 1.00 USD | -100.0% |
| 1999 Q2 | - USD | 0.0% |
| 1998 FY | 123.06 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 6.397% |
| Embecta Corp. | 749.9 Million USD | 59.288% |
| Dynavax Technologies Corporation | 182.11 Million USD | -67.641% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -317.84% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 37.733% |
| PainReform Ltd. | -15 Thousand USD | 2035453.333% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -926.16% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -3561.071% |
| SCYNEXIS, Inc. | 124.51 Million USD | -145.19% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -55011.73% |
| Cosmos Health Inc. | 4.34 Million USD | -6919.155% |
| Journey Medical Corporation | 52.52 Million USD | -481.297% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -3561.071% |
| Safety Shot Inc | -74.45 Thousand USD | 410139.352% |
| Alpha Teknova, Inc. | 10.29 Million USD | -2865.258% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 29.102% |
| Bright Green Corporation | -237.01 Thousand USD | 128911.135% |
| Procaps Group, S.A. | 239.56 Million USD | -27.438% |
| Theratechnologies Inc. | 62.12 Million USD | -391.402% |
| Harrow Health, Inc. | 90.55 Million USD | -237.154% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -6334.204% |
| Biofrontera Inc. | 16.62 Million USD | -1736.188% |
| DURECT Corporation | 6.83 Million USD | -4369.375% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 41.707% |
| Cronos Group Inc. | 6.99 Million USD | -4267.151% |
| OptiNose, Inc. | 62.35 Million USD | -389.629% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 30.795% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 100860.066% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -9896.258% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 1.448% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -5559.506% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -811.736% |
| Radius Health, Inc. | 307.71 Million USD | 0.783% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -2929.437% |
| ProPhase Labs, Inc. | 16.23 Million USD | -1780.06% |
| Phibro Animal Health Corporation | 312.48 Million USD | 2.299% |
| Procaps Group S.A. | 239.56 Million USD | -27.438% |
| Alvotech | -69.42 Million USD | 539.778% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -23348.771% |
| Viatris Inc. | 6.43 Billion USD | 95.258% |
| Rockwell Medical, Inc. | 8.7 Million USD | -3407.617% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -459.306% |
| SIGA Technologies, Inc. | 122.09 Million USD | -150.06% |
| Tilray Brands, Inc. | 223.35 Million USD | -36.692% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -629.517% |
| Shineco, Inc. | 882.16 Thousand USD | -34508.261% |
| PetIQ, Inc. | 252.74 Million USD | -20.797% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 41047.95% |
| Incannex Healthcare Limited | 12 Thousand USD | -2544091.667% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 83.474% |
| Alimera Sciences, Inc. | 61.17 Million USD | -399.106% |
| Silver Spike Investment Corp. | 8.1 Million USD | -3667.964% |
| Assertio Holdings, Inc. | 125.04 Million USD | -144.147% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 4482598.899% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -7184.437% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -4556.849% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 12767.249% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1025.873% |
| Hempacco Co., Inc. | -1.21 Million USD | 25210.603% |
| Talphera, Inc. | -4.89 Million USD | 6337.038% |
| Alvotech | -69.42 Million USD | 539.778% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | -37.726% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 56.972% |
| Currenc Group, Inc. | 17.35 Million USD | -1659.032% |
| Kamada Ltd. | 52.59 Million USD | -480.504% |
| Indivior PLC | 907 Million USD | 66.339% |
| Evoke Pharma, Inc. | 4.97 Million USD | -6032.12% |
| Flora Growth Corp. | 17.73 Million USD | -1621.181% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 12767.249% |
| Evolus, Inc. | 140.52 Million USD | -117.257% |
| HUTCHMED (China) Limited | 453.55 Million USD | 32.686% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 11.241% |
| Akanda Corp. | 111.44 Thousand USD | -273839.65% |